K. Ito

[Cross-contamination of Mycobacterium tuberculosis culture in clinical laboratories].

T. Yoshiyama, K. Ito, M. Takahashi, 1999, Kekkaku : [Tuberculosis].

Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation

K. Yoshimori, T. Yoshiyama, M. Shimoda, 2022, Medicine.

Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB.

A. Harries, P. Nunn, C. Kang'ombe, 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[Serodiagnosis with trehalose-6,6'-dimycolate of pulmonary tuberculosis].

C. Abe, K. Ito, M. Wada, 1997, Nihon Kyobu Shikkan Gakkai zasshi.

Auditing the new decentralised oral treatment regimens in Malawi.

A. Harries, P. Godfrey-Faussett, B. Squire, 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation

K. Yoshimori, T. Yoshiyama, M. Shimoda, 2022, Medicine.

[Limits of nucleic acid amplification tests for diagnosis of smear negative pulmonary tuberculosis].

T. Yoshiyama, K. Ito, M. Wada, 2000, Kekkaku : [Tuberculosis].

[Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability].

T. Yoshiyama, K. Ito, M. Wada, 1999, Kekkaku : [Tuberculosis].

Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000

S. Okabe, T. Matsumura, T. Nakagawa, 2023, Scientific reports.